Krystal Biotech, Inc. (KRYS): who owns it and who trades it
As of Nov 16, 2026, KRYS insiders reported 125 open-market sales worth $95.2M and no purchases in the last 12 months, with 86% of the sale value made under pre-set 10b5-1 plans. The largest seller was Suma Krishnan (President), with $34.3M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Krystal Biotech
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns KRYS
418 funds and institutions reported KRYS shares worth $11B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 4.42M | 14.99% | $1.6B | +1% |
| BlackRock, Inc. | 4.18M | 14.18% | $1.6B | +6% |
| Avoro Capital Advisors LLC | 2.89M | 9.80% | $1.1B | No change |
| Vanguard Portfolio Management LLC | 1.57M | 5.34% | $585M | +8% |
| State Street Corp | 1.35M | 4.58% | $502M | +3% |
| Vanguard Capital Management LLC | 1.24M | 4.21% | $461M | +6% |
| Soleus Capital Management, L.P. | 939,254 | 3.19% | $349M | -19% |
| Capital World Investors | 777,843 | 2.64% | $289M | -6% |
| Geode Capital Management, LLC | 698,993 | 2.37% | $260M | +9% |
| T. Rowe Price Associates | 687,400 | 2.33% | $255M | +42% |
| Hood River Capital Management LLC | 663,375 | 2.25% | $247M | +7% |
| Redmile Group, LLC | 632,005 | 2.14% | $235M | -6% |
| William Blair Investment Management, LLC | 570,153 | 1.93% | $212M | +40% |
| Frazier Life Sciences Management, L.P. | 481,307 | 1.63% | $179M | No change |
| Dimensional Fund Advisors LP | 476,038 | 1.61% | $177M | +2% |
| First Trust Advisors LP | 324,900 | 1.10% | $121M | -7% |
| Invesco Ltd. | 324,755 | 1.10% | $121M | +29% |
| Goldman Sachs Group Inc | 298,841 | 1.01% | $111M | +39% |
| Northern Trust Corp | 283,784 | 0.96% | $105M | +12% |
| Franklin Resources Inc | 261,917 | 0.89% | $97.3M | +46% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, KRYS insiders reported $0 of open-market purchases and $95.2M of sales. 86% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 1,992 | $362.65 | $722K | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 1,242 | $361.61 | $449K | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 2,320 | $360.47 | $836K | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 3,392 | $359.39 | $1.2M | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 3,180 | $358.42 | $1.1M | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 3,962 | $357.57 | $1.4M | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 565 | $363.34 | $205K | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 2,006 | $355.57 | $713K | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 520 | $354.54 | $184K | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 1,329 | $364.48 | $484K | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 826 | $365.41 | $302K | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 399 | $366.56 | $146K | Form 4 |
| Sep 4, 2026 | Suma Krishnan | President | Sale plan | 3,267 | $356.37 | $1.2M | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 1,358 | $364.48 | $495K | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 847 | $365.42 | $310K | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 405 | $366.56 | $148K | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 2,029 | $355.57 | $721K | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 3,297 | $356.37 | $1.2M | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 3,981 | $357.57 | $1.4M | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 3,143 | $358.42 | $1.1M | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 3,357 | $359.39 | $1.2M | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 2,266 | $360.46 | $817K | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 1,214 | $361.61 | $439K | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 2,010 | $362.65 | $729K | Form 4 |
| Sep 4, 2026 | Krish S Krishnan | CEO | Sale plan | 573 | $363.34 | $208K | Form 4 |
| Aug 14, 2026 | Dino A Rossi | Director | Sale | 40 | $333.23 | $13.3K | Form 4 |
| Aug 14, 2026 | Dino A Rossi | Director | Sale | 3,095 | $331.43 | $1M | Form 4 |
| Aug 14, 2026 | Dino A Rossi | Director | Sale | 4,896 | $330.36 | $1.6M | Form 4 |
| Aug 14, 2026 | Dino A Rossi | Director | Sale | 7,428 | $329.60 | $2.4M | Form 4 |
| Aug 14, 2026 | Dino A Rossi | Director | Sale | 1,687 | $328.52 | $554K | Form 4 |
| Aug 14, 2026 | Dino A Rossi | Director | Sale | 5,226 | $327.39 | $1.7M | Form 4 |
| Aug 14, 2026 | Dino A Rossi | Director | Sale | 2,287 | $326.60 | $747K | Form 4 |
| Aug 14, 2026 | Dino A Rossi | Director | Sale | 341 | $325.60 | $111K | Form 4 |
| Jun 25, 2026 | John Charles Thomas | Vice president | Sale plan | 1,000 | $347.27 | $347K | Form 4 |
| Jun 4, 2026 | Suma Krishnan | President | Sale plan | 320 | $300.75 | $96.2K | Form 4 |
| Jun 4, 2026 | Suma Krishnan | President | Sale plan | 593 | $302.25 | $179K | Form 4 |
| Jun 4, 2026 | Suma Krishnan | President | Sale plan | 247 | $303.17 | $74.9K | Form 4 |
| Jun 4, 2026 | Suma Krishnan | President | Sale plan | 400 | $304.89 | $122K | Form 4 |
| Jun 4, 2026 | Suma Krishnan | President | Sale plan | 480 | $305.87 | $147K | Form 4 |
| Jun 4, 2026 | Suma Krishnan | President | Sale plan | 240 | $311.65 | $74.8K | Form 4 |
| Jun 4, 2026 | Suma Krishnan | President | Sale plan | 12,729 | $307.81 | $3.9M | Form 4 |
| Jun 4, 2026 | Suma Krishnan | President | Sale plan | 3,803 | $308.89 | $1.2M | Form 4 |
| Jun 4, 2026 | Suma Krishnan | President | Sale plan | 2,801 | $309.95 | $868K | Form 4 |
| Jun 4, 2026 | Suma Krishnan | President | Sale plan | 2,039 | $310.94 | $634K | Form 4 |
| Jun 4, 2026 | Suma Krishnan | President | Sale plan | 1,348 | $307.09 | $414K | Form 4 |
| Jun 4, 2026 | Krish S Krishnan | CEO | Sale plan | 640 | $302.24 | $193K | Form 4 |
| Jun 4, 2026 | Krish S Krishnan | CEO | Sale plan | 176 | $303.17 | $53.4K | Form 4 |
| Jun 4, 2026 | Krish S Krishnan | CEO | Sale plan | 40 | $312.23 | $12.5K | Form 4 |
| Jun 4, 2026 | Krish S Krishnan | CEO | Sale plan | 964 | $311.36 | $300K | Form 4 |
| Jun 4, 2026 | Krish S Krishnan | CEO | Sale plan | 2,652 | $310.43 | $823K | Form 4 |
| Jun 4, 2026 | Krish S Krishnan | CEO | Sale plan | 2,784 | $309.49 | $862K | Form 4 |
| Jun 4, 2026 | Krish S Krishnan | CEO | Sale plan | 4,830 | $308.47 | $1.5M | Form 4 |
| Jun 4, 2026 | Krish S Krishnan | CEO | Sale plan | 544 | $304.81 | $166K | Form 4 |
| Jun 4, 2026 | Krish S Krishnan | CEO | Sale plan | 589 | $306.33 | $180K | Form 4 |
| Jun 4, 2026 | Krish S Krishnan | CEO | Sale plan | 11,461 | $307.68 | $3.5M | Form 4 |
| May 26, 2026 | John Charles Thomas | Vice president | Sale plan | 642 | $302.03 | $194K | Form 4 |
| Mar 4, 2026 | Suma Krishnan | President | Sale plan | 407 | $257.32 | $105K | Form 4 |
| Mar 4, 2026 | Suma Krishnan | President | Sale plan | 589 | $258.54 | $152K | Form 4 |
| Mar 4, 2026 | Suma Krishnan | President | Sale plan | 668 | $259.61 | $173K | Form 4 |
| Mar 4, 2026 | Suma Krishnan | President | Sale plan | 3,667 | $260.37 | $955K | Form 4 |
| Mar 4, 2026 | Suma Krishnan | President | Sale plan | 1,700 | $266.42 | $453K | Form 4 |
| Mar 4, 2026 | Suma Krishnan | President | Sale plan | 1,938 | $262.35 | $508K | Form 4 |
| Mar 4, 2026 | Suma Krishnan | President | Sale plan | 2,248 | $263.58 | $593K | Form 4 |
| Mar 4, 2026 | Suma Krishnan | President | Sale plan | 4,852 | $264.64 | $1.3M | Form 4 |
| Mar 4, 2026 | Suma Krishnan | President | Sale plan | 6,000 | $265.16 | $1.6M | Form 4 |
| Mar 4, 2026 | Suma Krishnan | President | Sale plan | 2,931 | $261.41 | $766K | Form 4 |
| Mar 4, 2026 | Krish S Krishnan | CEO | Sale plan | 483 | $257.31 | $124K | Form 4 |
| Mar 4, 2026 | Krish S Krishnan | CEO | Sale plan | 470 | $258.38 | $121K | Form 4 |
| Mar 4, 2026 | Krish S Krishnan | CEO | Sale plan | 1,377 | $259.87 | $358K | Form 4 |
| Mar 4, 2026 | Krish S Krishnan | CEO | Sale plan | 3,128 | $260.49 | $815K | Form 4 |
| Mar 4, 2026 | Krish S Krishnan | CEO | Sale plan | 920 | $266.56 | $245K | Form 4 |
| Mar 4, 2026 | Krish S Krishnan | CEO | Sale plan | 2,380 | $262.44 | $625K | Form 4 |
| Mar 4, 2026 | Krish S Krishnan | CEO | Sale plan | 2,043 | $263.70 | $539K | Form 4 |
| Mar 4, 2026 | Krish S Krishnan | CEO | Sale plan | 8,798 | $264.85 | $2.3M | Form 4 |
| Mar 4, 2026 | Krish S Krishnan | CEO | Sale plan | 2,439 | $265.59 | $648K | Form 4 |
| Mar 4, 2026 | Krish S Krishnan | CEO | Sale plan | 2,962 | $261.41 | $774K | Form 4 |
| Mar 2, 2026 | Kathryn Romano | Chief Accounting Officer | Sale plan | 750 | $267.60 | $201K | Form 4 |
| Feb 27, 2026 | Daniel Janney | Director | Sale plan | 2,373 | $276.17 | $655K | Form 4 |
| Feb 27, 2026 | Daniel Janney | Director | Sale plan | 9,430 | $275.45 | $2.6M | Form 4 |
| Feb 26, 2026 | Daniel Janney | Director | Sale plan | 2,638 | $276.32 | $729K | Form 4 |
| Feb 26, 2026 | Daniel Janney | Director | Sale plan | 5,103 | $275.28 | $1.4M | Form 4 |
| Feb 25, 2026 | Daniel Janney | Director | Sale plan | 700 | $275.00 | $192K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 2,425 | $274.90 | $667K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 1,674 | $268.67 | $450K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 930 | $269.50 | $251K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 1,891 | $267.37 | $506K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 4,339 | $266.62 | $1.2M | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 1,604 | $265.54 | $426K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 900 | $264.60 | $238K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 62 | $263.05 | $16.3K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 373 | $271.09 | $101K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 370 | $269.83 | $99.8K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 569 | $262.91 | $150K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 1,733 | $264.12 | $458K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 3,557 | $265.08 | $943K | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 8,986 | $266.18 | $2.4M | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 11,673 | $266.97 | $3.1M | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 6,671 | $268.04 | $1.8M | Form 4 |
| Feb 24, 2026 | Daniel Janney | Director | Sale plan | 3,963 | $268.97 | $1.1M | Form 4 |
| Feb 19, 2026 | Dino A Rossi | Director | Sale | 10,834 | $262.10 | $2.8M | Form 4 |
Latest 100 of 125 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Suma Krishnan | President, R&D, Director, 10% owner | – | $34.3M | Sep 4, 2026 |
| Krish S Krishnan | President and CEO, Director, 10% owner | – | $24.2M | Sep 4, 2026 |
| Daniel Janney | Director | – | $19.4M | Feb 27, 2026 |
| Dino A Rossi | Director | – | $13.2M | Aug 14, 2026 |
| Kathryn Romano | Chief Accounting Officer | – | $3.6M | Mar 2, 2026 |
| John Charles Thomas | EVP, General Counsel | – | $541K | Jun 25, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KRYS short interest
High short interest. 10.3% of KRYS shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 4%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.04M KRYS shares were sold short, 10.3% of the shares outstanding, up 3.7% from the report before. At the average daily volume of 248,952 shares, buying them all back would take about 12.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.04M | 10.28% | +4% | 248,952 | 12.2 |
| Oct 15, 2026 | 2.94M | 9.92% | -16% | 284,209 | 10.3 |
| Sep 30, 2026 | 3.48M | 11.74% | +10% | 310,502 | 11.2 |
| Sep 15, 2026 | 3.16M | 10.69% | -6% | 239,129 | 13.2 |
| Aug 31, 2026 | 3.35M | 11.31% | +4% | 219,245 | 15.3 |
| Aug 14, 2026 | 3.20M | 10.83% | +0% | 310,636 | 10.3 |
| Jul 31, 2026 | 3.20M | 10.82% | -8% | 770,966 | 4.2 |
| Jul 15, 2026 | 3.50M | 11.86% | -1% | 307,160 | 11.4 |
| Jun 30, 2026 | 3.52M | 11.93% | +12% | 489,255 | 7.2 |
| Jun 15, 2026 | 3.14M | 10.65% | -0% | 288,945 | 10.9 |
| May 29, 2026 | 3.15M | 10.68% | -1% | 194,305 | 16.2 |
| May 15, 2026 | 3.18M | 10.80% | +3% | 397,230 | 8.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Krystal Biotech company events
Krystal Biotech filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 2, 2026.
- Nov 2, 2026ResultsReleased financial results. Filing
- Oct 15, 2026AnnouncementShared information with investors. Filing
- Aug 3, 2026ResultsReleased financial results. Filing
- Jul 21, 2026AnnouncementKrystal Biotech, Inc. filed with the U.S. Patent and Trademark Office a response to an Office Action in connection with a published patent application relating to KB801, the Company’s investigational gene therapy product candidate for the treatment of neurotrophic keratitis. Filing
- May 20, 2026VoteReported shareholder vote results. Filing
- Feb 17, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Jan 8, 2026AnnouncementShared information with investors. Filing
- Dec 23, 2025LeadershipKirti Ganorkar gave notice of his resignation from the Board of Directors of Krystal Biotech, Inc. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Krystal Biotech financials
Famous investors that hold KRYS
4 of the 50 well-known investors we track reported holding KRYS in their latest 13F filing. The largest position is Ray Dalio's, worth $33.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ray Dalio · Bridgewater Associates | Q3 2026 | 99,920 | $33.2M | 0.1% | +83% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 63,120 | $21M | 0.0% | +6% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 44,548 | $14.8M | 0.0% | +1535% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 26,952 | $9M | 0.0% | -3% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named KRYS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 30, 2026 | Vanguard Portfolio Management | 13G/A | 4.4% |
| Oct 30, 2026 | Vanguard Portfolio Management | 13G/A | 4.4% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 11.6% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 11.6% |
Questions about Krystal Biotech, Inc. (KRYS) stock
Who owns the most KRYS stock?
The largest reported owner of Krystal Biotech, Inc. (KRYS) is FMR LLC (Fidelity), with 15.0% of the company. In total, 418 funds and institutions reported holding KRYS at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are KRYS insiders buying or selling?
In the last 12 months, KRYS insiders reported no open-market purchases and 125 sales worth $95.2M. The latest trade was on Sep 4, 2026. See every trade.
What is the short interest in KRYS?
As of Oct 30, 2026, 3.04M KRYS shares were sold short, 10.3% of the shares outstanding, up 3.7% from the report before. At the average daily volume of 248,952 shares, buying them all back would take about 12.2 trading days (days to cover). See the history.
Which famous investors hold KRYS?
4 of the 50 well-known investors we track reported KRYS in their latest 13F filing, including Ray Dalio, Jim Simons, Ken Griffin. The largest position is worth $33.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.